CNS Pharmaceuticals, Inc. Payments of Debt Issuance Costs
CNS Pharmaceuticals, Inc. (CNSP) reported Payments of Debt Issuance Costs of $46.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-12
- CNS Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2021-12-31 was $0.00.
- CNS Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2020-12-31 was $0.00.
- CNS Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2020-09-30 was $45.00K, a 1185.71% increase year-over-year.
- CNS Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- CNS Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- CNS Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2020 was $45.00K.
- CNS Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- CNS Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2018 was $95.20K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $46.00K 10-Q · filed 2026-08-12 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $0.00 10-K · filed 2022-03-03 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $45.00K derived: sum of 2 quarters · filed 2022-03-03 | $45.00K derived: sum of 3 quarters · filed 2022-03-03 | $45.00K 10-K · filed 2022-03-03 |
| 2020-09-30 | $45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $45.00K derived: sum of 2 quarters · filed 2021-11-12 | $45.00K 10-Q · filed 2021-11-12 | $3.48K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | -$41.52K derived: sum of 3 quarters · filed 2021-02-12 | -$38.02K derived: sum of 4 quarters · filed 2021-02-12 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-15 | -$41.52K derived: sum of 2 quarters · filed 2021-02-12 | -$38.02K derived: sum of 3 quarters · filed 2021-02-12 | -$13.03K derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-12-31 | -$41.52K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | -$38.02K derived: sum of 2 quarters · filed 2021-02-12 | -$13.03K derived: sum of 3 quarters · filed 2021-02-12 | $0.00 10-K · filed 2021-02-12 |
| 2019-09-30 | $3.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $28.50K derived: sum of 2 quarters · filed 2020-11-12 | $41.52K 10-Q · filed 2020-11-12 | $35.52K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $38.02K 10-Q · filed 2020-08-10 | $32.02K derived: sum of 3 quarters · filed 2020-08-10 | |
| 2019-03-31 | $13.03K 10-Q · filed 2020-05-15 | $7.03K derived: sum of 2 quarters · filed 2020-05-15 | ||
| 2018-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $95.20K 10-K · filed 2020-03-12 | ||
| 2018-09-30 | $101.20K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |